Fasnall benzenesulfonate is a potent, selective fatty acid synthase (FASN) inhibitor with IC50 of 3.71 uM for purified human FASN isolated from the BT474 cell line.
Fasnall potently blocked both acetate and glucose incorporation into total lipids, with IC50 values of 147 and 213 nM, respectively, in HepG2 cells.
Fasnall inhibits the incorporation of tritiated acetat in BT474 cells with IC50 of 5.84 uM.
Fasnall does not inhibit ACC (acetyl-CoA carboxylase), Hsp90, Hsp70, TRAP-1, DAP kinase 3, IRAK 2, AMPK α and γ subunits, NEK9, dengue nonstructural protein 5, malarial kinase PfPK9, and HSF-1.
Fasnall inhibited the proliferation of aggressive breast cancer cell lines, with profound changes in cellular lipid profiles, sharply increasing ceramides, diacylglycerols, and unsaturated fatty acids.
Fasnall (5-15 mg/kg) showed potent anti-tumor activity in the MMTV-Neu model of HER2+ breast cancer.